Respiratory Motion careers

We have commercialized a novel respiratory depression monitor, which provides physicians early indication of deteriorating or inadequate respiration in advance of existing technologies and of adverse events. At current standard of care, there are 350,000 respiratory arrests annually, 1 million post-surgical pulmonary complications, resulting in 5 million added hospital days and over $12B in cost. With the help of our technology, clinicians can now predict a deteriorating respiratory condition, prevent further compromise and negative outcomes, and reduce added costs.

We have validated the technology in thousands of patients in the acute and ambulatory settings in multiple clinical trials proving accuracy and clinical utility standalone and in combination with devices and therapeutics. The product is cleared for use in the US (FDA 510(K)), Canada, and Saudi Arabia, with CE mark, Japanese, and Korean regulatory approvals pending.